Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.
|
|
International Journal of Cancer (12.10.03) Vol. 107, No. 5, P. 804-810 - Thursday, May 06, 2004
Maaike C.G. Bleeker; Cornelis J.A. Hogewoning; Feja J. Voorhorst; Adrian J.C. van den Brule; Peter J.F. Snijders; Theo M. Starink; Johannes Berkhof; Chris J.L.M. Meijer
The male sexual partners of women with CIN were randomized for condom use (condom use = 68; noncondom use = 68) and screened for the presence of penile lesions (i.e., flat lesions, papular lesions and condylomata acuminata), and of HPV in their penile swabs by polymerase chain reaction testing. The outcome of this study was clinical regression of penile lesions defined as disappearance of lesions at penoscopy. Potentially prognostic factors including HPV status, lesion type and age were also studied.
Condom use shortened the median time to regression of flat penile lesions (7.4 months condom group vs. 13.9 months noncondom group) among the 57 male condom users. However, this effect was not seen for papular lesions. HPV-negative men showed a significantly shorter median time to regression of flat lesions (3.8 months) compared to men with either HPV- positive status (8.5 months) or inconsistent HPV status (13.1 months).
"Regression of flat penile lesions is HPV-dependent and accelerated by condom use," concluded the researchers. "This effect is probably the result of blocking viral transmission between sexual partners."
040506
AD040939
Copyright © 2004 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.